Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
What is the purpose of this trial?
The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC) compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48 weeks.
- 18 Years - 70 Years
- Bristol-Myers Squibb
- March 2011
- Last Updated:
- July 9, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT01309932